Document is current
Any future updates will be listed below
-
Authors
Manchikanti, Laxmaiah https://orcid.org/0000-0002-4201-9063
Pampati, Vidyasagar https://orcid.org/0009-0009-1701-8382
Kaye, Alan D. https://orcid.org/0000-0003-2464-0187
Abd-Elsayed, Alaa https://orcid.org/0000-0002-9890-7860
Shekoohi, Sahar https://orcid.org/0009-0007-4545-4523
Sanapati, Mahendra R. https://orcid.org/0000-0002-1047-0765
Soin, Amol https://orcid.org/0009-0007-0860-9696
Hirsch, Joshua A. https://orcid.org/0000-0001-5263-6535
- License Information
-
More Information
Article History
Received: 6 August 2025
Accepted: 1 March 2026
First Online: 14 March 2026
Declarations
:
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: Laxmaiah Manchikanti, Vidyasagar Pampati, MSc, Sahar Shekoohi, PhD, and Mahendra R. Sanapati, MD, declare no conflict of interest. Dr. Alan D Kaye is the Editor-in-Chief of CPHRs. Dr. Abd-Elsayed receives consulting fees from Medtronic, Avanos, and Curonix. Dr. Soin has several patents in non-opioid pain pharmaceuticals and neuromodulation (SCS and PNS) and artificial intelligence, has stock options with Neuros Medical, has received equipment, materials, drugs, medical writing, gifts or other services from Avanos for research and has other financial or nonfinancial interests with Alyea Therapeutics, Neuros Medical, Neuronoff, and Avanos.Dr. Hirsch receives grants or contracts from Neiman Health Policy Institute, is a consultant for Medtronic, Relievant, and Sanofi, and is the Chair CSMB of neurovascular studies for Balt: Rapid Medical. Alaa Abd-Elsayed, MD, is an editor of CPHRs.
